S&P 500 Healthcare Sector SEC Filings — May 26, 2026

26-05-2026

Editas Medicine presented preclinical data for EDIT-401 at the 94th EAS Congress, showing robust reductions in LDL-C, Lp(a), and ApoB in non-human primates. A single dose achieved 90% or greater mean reduction in LDL-C with durability through six months. The company plans to submit a CTN in Australia in mid-2026 and initiate a first-in-human trial in HeFH patients later in 2026, with early proof-of-concept data expected by end of 2026. However, higher doses (3 mg/kg and 6 mg/kg) showed liver enzyme increases and adverse observations, and functional liver editing rates were low at 12.4%.

• · EDIT-401 achieved rapid, dose-dependent mean reduction of approximately 90% in Lp(a) and ApoB.
• · Reductions in LDL-C, Lp(a), and ApoB were highly correlated, supporting a unified mechanism via LDL receptor upregulation.
• · Interim GLP toxicology results showed EDIT-401 was well-tolerated at 1.5 mg/kg with no adverse clinical observations, no notable liver enzyme elevations, and no liver histopathology findings.
• · Low functional liver editing rate of 12.4% at 1.5 mg/kg; low editing detected in adrenal gland, spleen, and ovary; no significant editing in other extrahepatic tissues.
• · At 3 mg/kg, minimal to marked liver enzyme increases and non-adverse liver findings; at 6 mg/kg, adverse clinical observations in one NHP.
• · Company received pre-IND feedback from FDA on nonclinical package, CMC plans, and study design.
• · Part 1 of Phase 1/2 trial expected to enroll ~18 HeFH patients in three dosing arms; Part 2 is a randomized, placebo-controlled expansion with ~28 patients.
• · Topline data from Part 1 expected in 2027.

26-05-2026

Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) filed a definitive proxy statement (DEF 14A) for a special meeting of stockholders to be held on June 18, 2026. The primary proposal seeks approval for one or more reverse stock splits with exchange ratios between 1-for-2 and 1-for-50 (aggregate not exceeding 1-for-60) to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company has 121,238,660 shares of common stock outstanding as of the April 23, 2026 record date, and a quorum requires at least 33⅓% of outstanding shares.

• · The special meeting will be held virtually via Zoom on June 18, 2026 at 1:00 p.m. Eastern Time.
• · The reverse stock split must be completed by March 31, 2027, with the aggregate exchange ratio not exceeding 1-for-60.
• · The company has changed its name multiple times: from Redwoods Acquisition Corp. (Jan 2022) to ANEW Medical, Inc. (Jun 2024) to Klotho Neurosciences, Inc. (Oct 2024) to Greenland Mines Ltd.
• · Proxy materials will be mailed to stockholders on or about May 28, 2026.
• · The board of directors has no interest in the proposals other than their share ownership.

26-05-2026

AITX announced that its subsidiary RAD has added 12 more RIO Minis at a massive construction site, as per a press release issued on May 26, 2026. The filing is an 8-K furnishing the press release under Item 8.01, with no financial details or performance metrics provided.

• · The press release is titled 'AITX's RAD Adds 12 More RIO Minis at Massive Construction Site'.
• · The filing is dated May 26, 2026, and is furnished under Item 8.01.

26-05-2026

Specificity, Inc. (SPTY) disclosed on May 22, 2026 that it will restate its 2025 annual financial statements due to errors from failing to review bank and credit card statements for accounts opened in mid-December 2025. The preliminary correction shows an understatement of expenses of $83,422, an understatement of revenues of $2,500, an understatement of liabilities of $121,122, an overstatement of additional paid-in capital of $40,000, and an understatement of cash of $202. The company believes the errors do not affect quarterly operating results in 2025 and is concurrently filing an amended 10-K/A and completing its delayed Q1 2026 10-Q.

• · The errors were identified on May 15, 2026.
• · The company delayed its Q1 2026 10-Q and filed a Form 12b-25.
• · The restatement amounts are subject to completion of CM3 Advisory review.
• · The company intends to file the amended 10-K/A and the Q1 2026 10-Q as soon as practical.

26-05-2026

News Corp filed an 8-K to disclose daily ASX disclosures related to its $1B stock repurchase program. The company is authorized to repurchase up to $1B in aggregate of Class A and Class B common stock. The filing includes forward-looking statements regarding the intent to repurchase shares from time to time.

• · The repurchase program covers both Class A common stock (NWSA) and Class B common stock (NWS).
• · Exhibits 99.1 and 99.2 contain the ASX disclosures for specific dates.
• · The company is required to provide daily ASX disclosure of repurchase transactions under ASX rules.

26-05-2026

Ryan Specialty Holdings, Inc. announced on May 26, 2026 that its Board of Directors approved a $300 million increase to its share repurchase program, bringing the total authorization to $600 million. As of May 22, 2026, after accounting for recent repurchases in Q2 2026, $300 million remains available under the program. The company may repurchase shares through open market, private transactions, or Rule 10b5-1 plans, subject to market conditions and liquidity.

• · The share repurchase program increase was approved by the Board of Directors on May 26, 2026.
• · Repurchases may be executed via open market, privately negotiated transactions, Rule 10b5-1 trading plans, or accelerated share repurchases.
• · The company is not obligated to purchase any shares and may suspend or discontinue the program at any time without notice.
• · The press release is attached as Exhibit 99.1 and incorporated by reference.

26-05-2026

At Thermo Fisher Scientific's 2026 Annual Meeting held on May 20, 2026, shareholders elected all 11 director nominees and ratified the appointment of PricewaterhouseCoopers LLP as auditor for fiscal year 2026. However, a non-binding advisory proposal on executive compensation (say-on-pay) was not approved, with 214.5 million votes against versus 99.9 million in favor.

• · All 11 director nominees were elected with votes ranging from 281.8 million (Dion J. Weisler) to 314.4 million (Debora L. Spar) in favor.
• · The ratification of PricewaterhouseCoopers LLP as independent auditor passed with 296.9 million votes for, 36.1 million against, and 1.0 million abstentions.
• · The say-on-pay proposal received 214.5 million votes against (68.2% of votes cast), indicating significant shareholder dissatisfaction with executive compensation.

26-05-2026

BRC Group Holdings, Inc. (formerly B. Riley Financial, Inc.) held its 2026 annual meeting on May 19, 2026, where all seven director nominees were elected, BDO USA, P.C. was ratified as the independent auditor for fiscal 2026, and the advisory vote on executive compensation was approved. While director elections and auditor ratification passed with strong support, the say-on-pay proposal received a notable 14.0% dissenting vote (1,742,371 votes against), indicating some shareholder concerns over executive compensation.

• · The company changed its name from B. Riley Financial, Inc. to BRC Group Holdings, Inc. effective November 4, 2014.
• · All seven director nominees were elected with votes for ranging from 11,465,094 (Renee E. LaBran) to 12,170,263 (Bryant R. Riley).
• · The highest vote against a director was for Renee E. LaBran with 1,039,801 votes against.
• · Ratification of BDO USA, P.C. as independent auditor passed with 21,730,428 votes for, 287,352 against, and 19,108 abstentions.
• · The advisory say-on-pay proposal received 10,707,112 votes for, 1,742,371 against, and 82,159 abstentions, with 9,505,246 broker non-votes.

26-05-2026

PNC Financial Services Group completed a public offering of $1.65 billion in senior notes on May 26, 2026, comprising $1.35 billion of 4.618% Fixed Rate/Floating Rate Senior Notes due 2029 and $300 million of Senior Floating Rate Notes due 2029. The notes were issued under an underwriting agreement with PNC Capital Markets, Citigroup, and Morgan Stanley. The filing does not disclose any negative or flat performance metrics, as it is a routine debt issuance event.

• · The notes were issued under an Indenture dated September 6, 2012, as supplemented by a First Supplemental Indenture dated April 23, 2021, with The Bank of New York Mellon as trustee.
• · The offering was made pursuant to a prospectus supplement filed May 21, 2026, and a base prospectus filed December 13, 2024, as part of an automatic shelf registration statement (File No. 333-283793).
• · The underwriting agreement was dated May 20, 2026, and the offering closed on May 26, 2026.

26-05-2026

Assembly Biosciences announced a priced underwritten offering of 3,358,602 common shares at $26.50 per share and pre-funded warrants for 415,000 shares at $26.499 per warrant, expecting approximately $100M in gross proceeds. The offering includes participation from Gilead Sciences, Commodore Capital, and other healthcare investors. Proceeds will fund clinical development and general corporate purposes, but the offering significantly dilutes existing shareholders.

• · Offering price per common share: $26.50; per pre-funded warrant: $26.499
• · Pre-funded warrants have an exercise price of $0.001 per share
• · Underwriters have a 30-day option to purchase up to 566,040 additional shares
• · Shelf registration statement declared effective March 27, 2026
• · Expected closing date for the offering: May 26, 2026
• · Joint book-running managers: Guggenheim Securities, UBS Investment Bank, and Mizuho; Lead manager: H.C. Wainwright & Co.

26-05-2026

TFS Financial CORP filed an 8-K on May 26, 2026, announcing that its mutual holding company, Third Federal Savings and Loan Association of Cleveland, MHC, will hold a special meeting of members on July 7, 2026, to vote on a proposal to waive the MHC's right to receive quarterly dividends totaling up to $1.27 per share that may be declared by the Company during the 12-month period following the member vote. This event is neutral as it involves a governance proposal that could affect dividend distribution but does not indicate any immediate financial impact.

• · The special meeting of MHC members is scheduled for July 7, 2026.
• · The waiver covers dividends declared during the 12-month period following the member vote.
• · The press release detailing the announcement is attached as Exhibit 99.1 to the 8-K.

26-05-2026

Pacira BioSciences issued a definitive additional proxy statement (DEFA14A) on May 26, 2026, responding to activist investor DOMA Perpetual Capital Management's misleading claims about the company's intellectual property strategy. Pacira defends its EXPAREL patent estate, highlighting a strengthened '495 patent, a new '940 patent providing protection into July 2044, and a strategic Fresenius Kabi settlement granting full exclusivity through early 2030 with gradual capped market entry until 2039. However, the company faces ongoing Paragraph IV generic challenges and litigation, with two recent ANDA filings that have not yet demonstrated bioequivalence or commercial-scale manufacturing.

• · The '495 patent was reexamined by the USPTO and reissued with amended claims adding volume limitations, now considered the strongest in the Erucic Acid Family.
• · The '940 patent, covering a new enhanced manufacturing process for EXPAREL, provides protection into July 2044 and is the first of a second patent family that has never been challenged or litigated.
• · Two recent Paragraph IV generic challenges have been filed, but they only mean ANDAs have been accepted for filing; no FDA approval or demonstrated bioequivalence at commercial scale has occurred.
• · Pacira has filed a patent infringement lawsuit in the United States District Court for the District of Delaware regarding the IVRA family patents.
• · The Fresenius Kabi settlement provides full exclusivity for EXPAREL through early 2030 and gradual capped market entry until 2039.
• · Pacira expects additional patents to be issued and added to its patent estate.

26-05-2026

Jackson Financial Inc. held its 2026 Annual Meeting and shareholders elected all 10 director nominees, ratified KPMG as auditor, and approved, on an advisory basis, executive compensation. The company reported that 62.6 million of 70.4 million shares outstanding were present at the meeting. There were no negative or flat metrics to report as all proposals passed with strong support; the lowest

26-05-2026

New Mountain Private Credit Fund reported an aggregate NAV of $962.5M and a fair value of its investment portfolio of $1,860.2M as of April 30, 2026, with an NAV per share of $23.32. The company sold 11,364 common shares in May 2026 at $23.32 per share, generating $0.3M. A regular monthly distribution of $0.19 per share was declared, payable on June 30, 2026 to holders of record May 29, 2026. Leverage stood at 1.06x debt-to-equity with $975.4M in debt outstanding and $1,510.0M in committed debt capacity, 100% floating rate (with 77% secured and 23% unsecured).

• · The company leveraged its floating rate exposure through interest rate swaps to treat fixed note payments as floating.
• · The offering is continuous on a monthly basis; the table shows total Shares issued and total consideration for the offering (not including DRIP shares).
• · As of April 30, 2026, 100% of debt capacity is floating rate; after swaps, the effective leverage is entirely floating.
• · No prior period comparisons were provided in the filing.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new/revised accounting standards.

26-05-2026

Lipocine Inc. presented Phase 3 clinical data for LPCN 1154 (oral brexanolone) at the ASCP Annual Meeting on May 26, 2026, highlighting results from a placebo-controlled trial for postpartum depression. The filing does not disclose specific efficacy or safety outcomes, nor does it provide any financial or operational metrics, making it impossible to assess performance trends or material financial impact.

• · The presentation and poster were furnished as Exhibits 99.1 and 99.2 to the 8-K.
• · The ASCP Annual Meeting took place May 26–29, 2026 in Miami Beach, FL.
• · No financial results, revenue, expenses, or balance sheet items were disclosed.
• · No prior-period comparisons or performance trends are available in this filing.

26-05-2026

Cintas Corporation (CTAS) provided an update on its pending acquisition of UniFirst Corporation, stating that it withdrew and refiled its FTC notification to allow more time for review, but maintains confidence in closing in the second half of calendar 2026. CEO Todd Schneider emphasized that all UniFirst employees—including route service representatives, sales, operations, and corporate staff—will be needed post-close, and that the combined company will serve approximately 1.5 million business customers across the U.S. and Canada. No negative or flat financial metrics were disclosed in this communication.

• · Cintas withdrew and refiled its FTC notification earlier in May 2026 to give regulators additional time to complete their review.
• · The company expects to close the transaction in the second half of calendar 2026.
• · Cintas stated it does not have a bench of people ready to serve an additional 300,000 customers, emphasizing the need for UniFirst employees post-close.
• · The combined organization will serve approximately 1.5 million business customers across the United States and Canada.

26-05-2026

Angel Oak Financial Strategies Income Term Trust (FINS) completed a $50M private placement of Series A Mandatorily Redeemable Preferred Shares (rated A3/Moody's) and a $40M private offering of Series C Senior Notes (rated A1/Moody's). The proceeds will refinance existing debt and support new investments. The Fund also set a record date of July 10, 2026 and an annual shareholder meeting for September 25, 2026, with proposals including trustee elections, a governance amendment to lower the trustee removal threshold, and ratification of the auditor.

• · MRPS due April 30, 2031; Series C Notes due July 8, 2030, Series B Notes due July 8, 2028.
• · Series C Notes are rated A1; MRPS rated A3 by Moody's.
• · Series C Notes will replace maturing Series A Senior Notes (2.35%, due July 8, 2026) in July 2026 via delayed draw.
• · Repurchase agreement leverage $75.5M (unrated in table).
• · Shareholders vote on six proposals: elect two Class II trustees, MRPS holders elect one Class III trustee, lower removal threshold from 75% to 66.67%, approve adjournments, ratify Cohen & Company as auditor, and other business.
• · Notice deadline for shareholder nominations/business: between 150th and 120th day prior to meeting, or 10 days after public announcement if later.

26-05-2026

CVB Financial Corp. announced the retirement of Richard Wohl as Executive Vice President and General Counsel, effective June 5, 2026. In recognition of his service since October 2011, the Compensation Committee accelerated the vesting of restricted stock awards totaling 17,904 shares, valued at approximately $364,346 based on the May 22, 2026 closing price of $20.35. No financial performance metrics or period-over-period comparisons were provided in this filing.

• · The accelerated awards include: 3,074 shares originally vesting January 2027; 5,816 shares originally vesting in two equal increments January 2027 and January 2028; and 9,014 shares originally vesting in three equal increments January 2027, January 2028 and January 2029.
• · The acceleration is effective June 5, 2026, the same date as Mr. Wohl's retirement.
• · The awards were granted under the Company's 2018 Equity Incentive Plan.
• · The closing stock price used for valuation was $20.35 on May 22, 2026.

26-05-2026

Precision BioSciences, Inc. filed an 8-K on May 26, 2026, reporting that stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation to limit the personal liability of directors and officers for monetary damages for breaches of fiduciary duty, to the fullest extent permitted by Delaware law. The amendment was adopted at a stockholders' meeting and executed on May 22, 2026. No financial figures or performance metrics were disclosed in this filing.

• · The amendment was approved by stockholders at a meeting and certified on May 22, 2026.
• · The amendment modifies Article SEVENTH of the Certificate of Incorporation to eliminate or limit director and officer liability for monetary damages for breaches of fiduciary duty, subject to Delaware law limitations.
• · The amendment does not apply retroactively to acts or omissions occurring before the amendment.

26-05-2026

Summit Financial Wealth Advisors, LLC filed its Form 13F-HR for the quarter ended March 31, 2026, reporting a portfolio of 193 equity holdings with a total market value of approximately $705.4 million. The largest positions include Schwab Strategic Trust US Dividend Equity ETF ($59.0M), Vanguard Whitehall Funds International High Dividend Yield ETF ($60.1M), and iShares Trust Preferred and Income Securities ETF ($20.5M). The filing reflects a diversified portfolio with significant exposure to large-cap ETFs, energy, and financial sectors.

• · The portfolio includes 193 equity holdings with a total market value of $705,414,528.
• · Top holdings by value: Vanguard Whitehall Fds Intl High Div ETF ($60,096,864), Schwab Strategic Tr US Dividend Eq ETF ($58,958,410), Vanguard Index Fds Growth ETF ($48,830,692).
• · Significant positions in energy sector: Exxon Mobil ($8,311,618), Chevron ($6,882,435), Valero Energy ($15,900,085), ONEOK ($2,396,398), Energy Transfer ($544,902).
• · Large technology holdings: Apple ($11,148,521), Microsoft ($5,294,903), Alphabet Class C ($3,646,177), Broadcom ($2,546,422), NVIDIA ($2,508,536).
• · Major financial holdings: JPMorgan Chase ($3,420,287), Bank of America ($818,610), Citigroup ($645,024), US Bancorp ($5,352,661).
• · Healthcare exposure includes: UnitedHealth ($8,092,265), Eli Lilly ($1,048,601), Merck ($1,185,699), Pfizer ($2,447,491).
• · Industrial holdings: Cummins ($16,813,781), Lockheed Martin ($8,301,297), Boeing ($2,019,155), Eaton Corp ($8,452,457).
• · The filing is for the quarter ended March 31, 2026, submitted on May 26, 2026.
• · All holdings are reported with sole voting and dispositive power.

26-05-2026

Core Scientific appointed Steve Smith, CEO of Zayo Group and former CEO of Equinix, to its Board of Directors effective May 26, 2026. Mr. Smith brings over 35 years of leadership in data center and digital infrastructure, having scaled Equinix's revenue from ~$400M to over $4B and integrated more than 20 acquisitions. The appointment supports Core Scientific's AI infrastructure build-out and long-term power infrastructure strategy, though no specific financial impact or performance metrics were disclosed.

• · Steve Smith will serve on the Company's Nominating and Corporate Governance Committee.
• · Mr. Smith graduated from the U.S. Military Academy at West Point with a Bachelor of Science in Engineering.
• · Core Scientific operates facilities in Alabama (1), Georgia (2), Kentucky (1), North Carolina (1), North Dakota (1), Oklahoma (1) and Texas (4).
• · The majority of Core Scientific's revenue is derived from high-density colocation services, with the remainder from digital asset mining and hosting.
• · The Company is repurposing its remaining mining facilities to support its high-density colocation services business as circumstances allow.

26-05-2026

Ruggaard & Associates LLC filed its quarterly 13F-HR for the period ending March 31, 2026, disclosing 139 equity holdings with a total market value of approximately $252.4 million. The filing shows a concentrated portfolio with top positions in Microsoft, Apple, Alphabet, Amazon, and NVIDIA, while also including significant holdings in fixed-income and sector ETFs. The portfolio reflects a mix of large-cap growth, value, and income-oriented strategies.

• · The filing was signed by Ryan Ruggaard, Director of Research & Chief Compliance Officer, on May 26, 2026.
• · The portfolio includes 139 positions with a total market value of $252,372,365.
• · Top holdings by value include Microsoft Corp ($1,946,770), Apple Inc ($2,006,206), Alphabet Inc ($2,258,321), Amazon.com Inc ($2,405,245), and NVIDIA Corporation ($1,440,407).
• · The portfolio contains a mix of common stocks, ETFs, and ADRs across various sectors including technology, financials, energy, healthcare, and consumer goods.
• · Notable fixed-income exposure includes iShares iBonds ETFs, PIMCO bond ETFs, and Capital Group fixed-income ETFs.
• · The filing does not include any period-over-period comparisons, so no trends or changes in holdings can be assessed.

26-05-2026

Federal Home Loan Bank of Cincinnati filed an 8-K reporting the issuance of Consolidated Bonds totaling $575.5 million on trade dates May 20-21, 2026. The bonds include fixed-rate callable and variable-rate non-callable instruments, with maturities ranging from 2027 to 2036. These obligations are joint and several among the 11 Federal Home Loan Banks and are not guaranteed by the U.S. government.

• · The bonds are joint and several obligations of all 11 Federal Home Loan Banks.
• · The bonds are not guaranteed by the United States government.
• · Consolidated Discount Notes with maturities up to 360 days are not included in the schedule.
• · The filing does not address interest-rate exchange agreements or other derivatives associated with the bonds.

26-05-2026

Tompkins Financial Corporation held its 2026 Annual Meeting on May 19, 2026, with 11,651,674 shares represented (80.8% of 14,414,482 outstanding shares). Shareholders elected all 11 director nominees, approved the say-on-pay proposal, and ratified KPMG LLP as independent auditor for 2026. All proposals passed with strong support, though the say-on-pay vote received 220,037 against and 107,314 abstentions, indicating some shareholder dissent.

• · Record date for the meeting was March 20, 2026.
• · All 11 director nominees were elected with votes for ranging from 9,675,381 (Patricia A. Johnson) to 9,835,038 (Heidi M. Davidson).
• · Broker non-votes totaled 1,766,890 on director elections and the say-on-pay proposal.
• · Say-on-pay received 9,557,433 for, 220,037 against, and 107,314 abstentions.
• · Ratification of KPMG LLP received 11,342,943 for, 205,550 against, and 103,181 abstentions (no broker non-votes as it is a routine matter).

26-05-2026

Velocity Financial, Inc. held its Annual Meeting of Shareholders on May 21, 2026, where all eight director nominees were re-elected and shareholders approved, on an advisory basis, the compensation of named executive officers for 2025. Additionally, shareholders ratified RSM US LLP as the company's independent auditor for 2026. All proposals passed with strong shareholder support, though a notable number of votes were cast against director Alan H. Mantel (121,835 against) and John A. Pless (261,726 against).

• · Broker non-votes totaled 1,181,801 for each director election and for the advisory compensation vote.
• · Proposal III (ratification of auditor) received 25,860,650 votes for, 2,294 against, and 6,528 abstentions, with no broker non-votes.
• · Director John A. Pless received the highest number of against votes (261,726) among all director nominees.
• · Director Alan H. Mantel received 121,835 against votes, the second highest.

26-05-2026

Provident Financial Services, Inc. (PFS) entered into an Amended and Restated Executive Chairman Agreement and an Amended and Restated Change in Control Agreement with Executive Chairman Christopher Martin on May 21, 2026. The agreements extend the term to May 21, 2028, and introduce a Director Emeritus role for three years following service termination, along with a revised change-in-control severance calculation based on remaining term days and average annual compensation. No financial figures or period-over-period comparisons were provided in this filing.

• · The Amended and Restated Executive Chairman Agreement expires on May 21, 2028.
• · The Amended and Restated Change in Control Agreement also expires on May 21, 2028.
• · Under the Change in Control Agreement, severance upon qualifying termination equals (remaining days in term / 365) multiplied by the average of Mr. Martin's Annual Compensation over the three completed calendar years preceding the change in control.
• · Mr. Martin will receive continued insurance coverage at no cost for the remainder of the term after a qualifying termination.
• · The agreements supersede and replace prior agreements with substantially identical terms except for the term extension and new Director Emeritus provision.

26-05-2026

Edgewell Personal Care Company filed an 8-K on May 26, 2026, announcing the departure of Chief Supply Chain Officer Paul R. Hibbert effective June 1, 2026, and the appointment of Anthony Freve as his successor effective the same date. The filing also includes Regulation FD disclosure and exhibits.

• · Departure effective June 1, 2026
• · Appointment effective June 1, 2026
• · Mr. Hibbert eligible for Executive Severance Plan payments
• · Filing date May 26, 2026

26-05-2026

CBL & Associates Properties, Inc. held its annual meeting on May 21, 2026, where all seven director nominees were elected, shareholders ratified Deloitte & Touche as the independent auditor for fiscal year 2026, and the executive compensation program was approved on an advisory basis. All proposals passed with strong shareholder support, though the executive compensation vote had a notable 8.8% abstention rate (including broker non-votes).

• · The annual meeting was held on May 21, 2026, and the 8-K was filed on May 26, 2026.
• · All seven director nominees were elected with votes cast ranging from 23,819,393 (David M. Fields) to 25,210,106 (Stephen D. Lebovitz).
• · David M. Fields received the highest number of votes withheld (1,494,244), representing about 5.9% of votes cast for that nominee.
• · The ratification of Deloitte & Touche received 26,415,581 votes for, 458,487 against, and 17,590 abstentions, with no broker non-votes.
• · The executive compensation advisory vote had 22,773,554 votes for, 346,714 against, and 2,193,369 abstentions, plus 1,578,021 broker non-votes.
• · The company's common stock trades on the New York Stock Exchange under the symbol CBL.

26-05-2026

The Federal Home Loan Bank of New York disclosed a new debt issuance via an 8-K filing on May 26, 2026. The issuance is a $500,000,000 optional principal redemption (callable) bond with a European call style (redeemable only on Nov 23, 2026) and a fixed coupon of 3.887%, maturing Feb 23, 2027. The bond was settled on May 21, 2026.

• · Trade date: May 20, 2026; Settlement date: May 21, 2026; Maturity date: Feb 23, 2027.
• · Next pay date: Nov 23, 2026; Next call date (optional redemption): Nov 23, 2026.
• · CUSIP: 3130BAUE5.
• · The bond is classified as Fixed Rate, Constant sub-type (interest paid at fixed rate over life).
• · No period-over-period comparisons are available because this is a discrete new issuance filing.

26-05-2026

New Peoples Bankshares Inc. held its 2026 Annual Shareholders' Meeting on May 19, 2026, where shareholders elected five directors and ratified the appointment of Yount, Hyde & Barbour, P.C. as independent auditor for fiscal year 2026. All director nominees received overwhelming support with over 99.7% of votes cast in favor, and the auditor ratification passed with 99.9% approval. The filing also includes a management presentation furnished as Exhibit 99.1.

• · Record date for the meeting was March 25, 2026.
• · Broker non-votes totaled 1,622,119 shares on all director elections.
• · Auditor ratification had 16,264,554 votes FOR, 7,355 AGAINST, and 16,802 ABSTAIN.
• · The company's common stock is not listed on any national exchange (no trading symbol).

26-05-2026

Senti Holdings, Inc. issued a Senior Secured Convertible Note with an original principal amount (unspecified). The note carries a 200% principal repayment at maturity, default interest at 12% per annum, and allows exchange into common stock at a conversion price determined by dividing the outstanding amount by the exchange price. The filing details exchange mechanics, including DTC participation and registration requirements, and includes provisions for events of default and cure periods. No specific financial figures or performance metrics are provided in this exhibit.

• · Original Principal Amount is unspecified in the exhibit.
• · Maturity Date is blank, subject to extension upon Event of Default or Change of Control.
• · Default Interest accrues at 12% per annum only after an Event of Default occurs.
• · Exchange Right allows conversion into Issuer Common Stock at any time before Maturity Date.
• · Exchange mechanics require DTC participation or physical certificate delivery if registration is not effective.
• · Issuer must deliver shares within specified Trading Days after Exchange Notice; failure triggers Event of Default and Holder may void exchange.
• · Transfer Agent must participate in DTC Fast Automated Securities Transfer Program while Notes are outstanding.

26-05-2026

At the 2026 Annual Meeting on May 21, 2026, stockholders of Spruce Biosciences elected three Class III directors (Michael Grey, Camilla V. Simpson, Javier Szwarcberg) with strong support but relatively high withheld votes for Simpson (~36%). The advisory vote on executive compensation passed with only ~62% support, reflecting notable opposition, while the frequency of future advisory votes was set to annual. The ratification of BDO USA as auditor was overwhelmingly approved.

• · Record date was March 24, 2026, with 1,372,278 shares outstanding.
• · Quorum was 903,893 shares (65.86%).
• · Broker non-votes were 604,019 for all non-routine items.
• · Proposal 2 (ratification of auditor) was routine, so no broker non-votes were cast.
• · About 36% of votes cast on Proposal 3 (say-on-pay) were against or abstained, indicating significant shareholder dissent.
• · Frequency vote strongly favored annual (297,804) vs. 2 years (1,049) or 3 years (804).
• · Next required frequency vote no later than 2032 Annual Meeting.

26-05-2026

Medallion Financial Corp filed a DEFA14A (additional proxy soliciting materials) on May 26, 2026, urging shareholders to read its definitive proxy statement for the 2026 Annual Meeting. The filing includes links to press releases and references total shareholder return calculations and a $75.0 million senior notes private placement led by J.P. Morgan Investment Management.

• · Total shareholder return calculated from Jan. 31, 2017 to Feb. 2, 2026 (reference to transformation plan press release).
• · Total shareholder return calculated from June 11, 2024 to Feb. 2, 2026.
• · FactSet data referenced for periods Dec. 1, 2014 to Nov. 18, 2018 and Jan. 1, 2025 to May 15, 2026.
• · Driver Management nominated three independent candidates for election to Codorus Valley Bancorp's board (reference).